Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Interleukin 12-Primed Activated T Cells As Therapy For Patients With Metastatic Melanoma (Phase I)

NCT00016055 is registered in ClinicalTrials.gov with St. Luke's Medical Center as lead sponsor.

NCT NCT00016055
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00016055 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Interleukin 12-Primed Activated T Cells As Therapy For Patients With Metastatic Melanoma (Phase I)
Lead sponsor
St. Luke's Medical Center
Phase
Phase 1
Overall status
Unknown status
Start date
November 30, 2000
Completion date
Not reported
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma (skin)